论文部分内容阅读
目的探讨埃索美拉唑三联疗法治疗幽门螺杆菌相关消化性溃疡的临床疗效。方法 92例幽门螺杆菌相关消化性溃疡患者,随机分为研究组(46例)和对照组(46例),研究组采用埃索美拉唑三联疗法治疗,对照组采用兰索拉唑片三联疗法治疗,对比两组患者临床疗效。结果研究组临床总有效率、幽门螺杆菌根除率分别为95.65%、91.30%,与对照组76.09%、67.39%对比,差异具有统计学意义(P<0.05);两组不良反应发生率对比差异无统计学意义(P<>0.05)。结论给予幽门螺杆菌相关消化性溃疡患者埃索美拉唑三联疗法治疗,能有效改善患者临床症状,提高幽门螺杆菌根除率。
Objective To investigate the clinical efficacy of esomeprazole triple therapy in the treatment of Helicobacter pylori-associated peptic ulcer. Methods Ninety-two H. pylori-associated peptic ulcer patients were randomly divided into study group (n = 46) and control group (n = 46). The study group was treated with esomeprazole triple therapy, while the control group was treated with lansoprazole- Therapeutic treatment, compared the clinical efficacy of two groups of patients. Results The total clinical effective rate and Helicobacter pylori eradication rate in the study group were 95.65% and 91.30%, respectively, which were significantly different from those in the control group (76.09% and 67.39%, P <0.05). There was significant difference between the two groups in the incidence of adverse reactions Not statistically significant (P <0.05). Conclusion The triple therapy of esomeprazole in patients with peptic ulcer associated with Helicobacter pylori can effectively improve the clinical symptoms and improve the eradication rate of Helicobacter pylori.